Search

GLAXOSMITHKLINE'S RHEUMATOID ARTHRITIS PROSPECT MISSES PHASE 2 ENDPOINT

GlaxoSmithKline has missed the primary endpoint in a phase 2 trial of rheumatoid arthritis prospect GSK3196165. The highest dose of...

Warp Drive's Odyssey Ends with a Buyout-By Revolution, Not Sanofi

WARP DRIVE'S ODYSSEY ENDS WITH A BUYOUT-BY REVOLUTION, NOT SANOFI

Warp Drive Bio started up in 2012 with a potential buyer, Sanofi, already in place. Six years later the Cambridge, MA, company is being...

 
 
 
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

Science ‘Mojo' and an Executive Dream Team: CEO Emma Walmsley's Bold Prescription for Reviving GlaxoSmithKline

SCIENCE ‘MOJO' AND AN EXECUTIVE DREAM TEAM: CEO EMMA WALMSLEY'S BOLD PRESCRIPTION FOR REVIVING GLAXOSMITHKLINE

EMMA WALMSLEY was just six weeks into her tenure as CEO of GlaxoSmithKline, the $38.9 billion British pharmaceutical firm, when "Glaxit"...

 
 
 

OXFORD REGENERATIVE MEDICINE SPINOUT BRINGS ON GLAXOSMITHKLINE DRUG HUNTER AS CSO

The University of Oxford's regenerative drug discovery spinout OxStem Limited has appointed Georg Terstappen as chief scientific officer,...

Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
 
 
 
Bio Roundup: An Alzheimer's Head-Scratcher, OUTBio, GSK & Gilead Shakeups  

BIO ROUNDUP: AN ALZHEIMER'S HEAD-SCRATCHER, OUTBIO, GSK & GILEAD SHAKEUPS  

The devil is in the details, and key clinical trial results made that abundantly clear this week. Eisai and partner Biogen released...

Here's the email 23andMe sent its customers after GSK bought a $300 million stake in the company

HERE'S THE EMAIL 23ANDME SENT ITS CUSTOMERS AFTER GSK BOUGHT A $300 MILLION STAKE IN THE COMPANY

Kimberly White/Getty 23andMe on Wednesday announced a partnership with pharma giant GlaxoSmithKline to develop new treatments for diseases...

 
 
 
Why GSK just made a $300 million bet on 23andMe's approach to finding new medicines

WHY GSK JUST MADE A $300 MILLION BET ON 23ANDME'S APPROACH TO FINDING NEW MEDICINES

Getty Images/Kimberly White Consumer genetics company 23andMe is teaming up with UK drug giant GlaxoSmithKline to develop new drugs. As...

FDA ADCOMM BACKS GLAXOSMITHKLINE'S ONE-SHOT P. VIVAX MALARIA THERAPY

GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax-one of the most common...

 
 
 
 
 
 

ASCO: ADAPTIMMUNE BUILDS CASE FOR GLAXOSMITHKLINE-PARTNERED T-CELL THERAPY

Adaptimmune has presented updated clinical data on its T-cell therapies. The latest readouts link the GlaxoSmithKline-partnered NY-ESO...

 
 
 
Propeller Health Raises $20M to Move Beyond Respiratory Disease

PROPELLER HEALTH RAISES $20M TO MOVE BEYOND RESPIRATORY DISEASE

Since launching in 2010, Propeller Health has kept its focus on developing connected devices and complementary software for patients...

 
 
 

GALECTO BRINGS ON GSK'S FIBROSIS LEAD AS CMO

Galecto Biotech has hired Richard Marshall, M.D., a medicines development leader at GlaxoSmithKline, to be its new chief medical officer...